FHL-101 is under clinical development by Forest Hills Partners Hong Kong and currently in Phase I for Unspecified Neurologic Disorders. According to GlobalData, Phase I drugs for Unspecified Neurologic Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the FHL-101 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FHL-101 overview
FHL-101 is under development for the treatment of Parkinson’s disease, Huntington’s disease and unspecified neurologic disorders. It is administered through oral route.
It was also under development for glycine encephalopathy (also known as nonketotic hyperglycinemia, Inherited Metabolic Disorders), urea cycle disorders, farber disease, GM1 gangliosidosis, glycogen storage disorders.
Forest Hills Partners Hong Kong overview
Forest Hills Partners Hong Kong is engaged in the development of therapeutic drugs to treat neurogenerative disease such as alzheimer’s and parkinson’s diseases. It offers anti-aging cosmeceutical products including PN fillers, dermal HA fillers and serums. The company is headquartered in Wan Chai, Hong Kong.
For a complete picture of FHL-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
